logo

DermNet NZ


Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Bimatoprost

Dermatological indications

Bimatoprost is a prostaglandin analogue sold in the US, Canada and Europe by the pharmaceutical company Allergan. It was first marketed under the trade name Lumigan® (bimatoprost ophthalmic solution 0.01% or 0.03%) to reduce intraocular pressure in patients with glaucoma or ocular hypertension.

Researchers noticed the drug had the side effect of stimulating eyelash growth and darkening of the eyelashes in patients with glaucoma.

Allergan re-applied for US Food and Drug Administraton (FDA) approval for bimatoprost for the cosmetic purpose of eyelash growth under the new name Latisse®. In December 2008, bimatoprost ophthalmic solution 0.03% was approved by the FDA as a treatment for eyelash hypotrichosis (inadequate or not enough eyelashes).

Effect of bimatoprost solution on eyelashes Effect of bimatoprost solution on eyelashes Effect of bimatoprost solution on eyelashes
Effect of bimatoprost solution on eyelashes

Off-label uses

How does bimatoprost work?

What precautions should you take when using bimatoprost?

Side effects

Clinical study experience

The most frequently reported adverse events (< 4% patients) with bimatoprost solution are:

Postmarketing experience

The following reactions have been identified during postmarketing use of bimatoprost solution in clinical practice.

Use in specific populations

Pregnancy

There are no adequate and well-controlled studies of the use of bimatoprost ophthalmic solution 0.03% in pregnant women. Because animal reproductive studies are not always predictive of human response, bimatoprost solution should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation

It is not known whether bimatoprost solution is excreted in human milk. Caution should be exercised when bimatoprost is administered to a nursing woman.

Paediatric use

Safety and effectiveness in children have not been established.

Geriatric use

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

Hepatic impairment

In patients with a history of liver disease or elevated liver enzymes, bimatoprost solution 0.03% had no adverse effect on liver function over a period of 48 months.

Related information

References:

On DermNet NZ:

Other websites:

Books about skin diseases:

See the DermNet NZ bookstore

Author: Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK)

Note:

The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website.

DermNet NZ does not provide an on-line consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.